SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) Garcia-Manero, G., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M., Savoie, M., Medeiros, B. C., Sekeres, M. A., Lin, T. L., Uy, G. L., Powell, B. L., Kolitz, J. E., Larson, R. A., Stone, R. M., Claxton, D. F., Essell, J., Luger, S., Mohan, S. R., Moseley, A., Appelbaum, F. R., Erba, H. P. AMER SOC HEMATOLOGY. 2016

View details for Web of Science ID 000394446802158